This article considerS pyrogens of microbial origin and the theoretical risks they pose to pharmaceutical products. The focus of the article IS with non-endotoxin pyrogens. The reasons for this are because of the voluminous content written about endotoxins and because non-endotoxin pyrogens often receive little discussion. Despite the low risk posed by non-endotoxin pyrogens, questions of their occurrence and risks are sometimes raised by regulators through inspections and by assessors during license changes and submissions. When such questions arise the pharmaceutical manufacturer is often called upon to undertake a risk assessment. Some of the information outlined within this article could be helpful in developing such an assessment.
This content is only available to IVT members.
Get help maintaining your knowledge in GXP. Read More!
If you are already a member and you do not have access to this article, upgrade your membership.
Need help? Read our FAQs.